3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
8
Completed
3
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Colorectal Neoplasms
5
Melanoma
4
Carcinoma, Renal Cell
4
Carcinoma, Transitional Cell
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasm Metastasis
2
Mesothelioma
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Advanced Solid Tumor
2
Adenocarcinoma Of Esophagus
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Testicular Germ Cell Tumor
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Nasopharyngeal Carcinoma
1
Lung Neoplasms
1
Locally Advanced Rectal Cancer
1
Interventions
pembrolizumab
29
Carboplatin
27
Specimen Handling
21
durvalumab
20
Pemetrexed
18
Cisplatin
17
Paclitaxel
16
atezolizumab
15
Nivolumab
15
Magnetic Resonance Spectroscopy
15
osimertinib
11
Radiosurgery
11
Radiotherapy
10
Immunoglobulin G
10
Etoposide
10
Docetaxel
10
Disulfides
10
Radiation
9
Taxes
8
Gemcitabine
8
Biopsy
8
Blood Specimen Collection
7
Standard of Care
6
Practice Guidelines as Topic
6
Ipilimumab
6
Surveys and Questionnaires
5
Platinum
5
Bronchoscopy
5
Bevacizumab
5
Ramucirumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lung Neoplasms
×
tislelizumab
×
Clear all
NCT04699188
2026-03-18
KontRASt-01
Novartis
Phase 1/2
Active not recruiting
344 enrolled